Before founding Nextech Invest Ltd. in 1998, Scheidegger was managing director and member of the board of the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. Earlier he served as the first managing director of the Swiss Supercomputing Center (CSCS), and lead an international drug-discovery project at Ciba-Geigy (today Novartis), Japan. He is co-initiator of Venture 98, the first Swiss national business plan contest. Scheidegger holds a PhD in biochemistry and microbiology from the University of Basel, Switzerland, has completed a post-doctorate research fellowship in enzymology at the University of Kyoto, Japan, and an executive training program at Harvard Business School, USA. He has over 15 years of investment experience in the biotechnology industry.
Currently, Alfred Scheidegger is on the board of directors at Cleave Biosciences, Molecular MD (observer), Dottikon ES Holding and Rising Tide Foundation. Past board representations include Agensys (acquired by Astellas), Ganymed Pharmaceuticals (acquired by ATS, later Astellas), MacroGenics (NASDAQ: MGNX), Sunesis Pharmaceuticals (NASDAQ: SNSS), Tetralogic Pharmaceuticals (NASDAQ: TLOG), and Tracon Pharma (NASDAQ: TCON).